Formic Acid

Formic Acid

SCHEMBL313953

CN1CCC(COC(=O)N2CCN(c3ccccc3)CC2)CC1.O=CO

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.49
CHRM4 P08173 4/20 0.46
ADAM10 O14672 1/20 0.45
ERBB2 P04626 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
GPR119 Q8TDV5 1/20 0.44
HTR1A P08908 2/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
DRD1 P21728 1/20 0.43
HRH2 P25021 1/20 0.43
HTR1B P28222 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314396 0.95 KDM1A (0.53) KDM1ACHRM4ADAM10ERBB2MMP2
SCHEMBL313986 0.84 MAPT (0.54) KDM1ACHRM4MAPTLMNAKDM4E
SCHEMBL314647 0.83 CHRM4 (0.55) KDM1ACHRM4MAPTLMNAKDM4E
SCHEMBL315151 0.83 LMNA (0.50) CHRM4MAPTLMNAKDM4EGAA
SCHEMBL314370 0.83 GPR119 (0.52) CHRM4MAPTLMNAGPR119ALDH1A1
SCHEMBL314479 0.82 L3MBTL1 (0.60) MAPTLMNAKDM4EGAAHTR2A
SCHEMBL314976 0.82 CHRM4 (0.52) CHRM4LMNAGPR119HTR1ATMEM97
SCHEMBL314335 0.81 KDM1A (0.53) KDM1ACHRM4MAPTLMNAKDM4E
Formic Acid SCHEMBL314781 0.80 HTR1A (0.52) MAPTLMNAKDM4EGAAHTR1A
SCHEMBL1183925 0.78 MAPT (0.46) CHRM4ADAM10ERBB2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2012-02-22 EP disclosed
US-8093248-B2 Compounds useful for the treatment of conditions associated with weight gain ASTRAZENECA AB (PUBL) (SE) 2012-01-10 US disclosed
EP-2234992-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090281087-A1 Compounds II BIOVITRUM AB (SE) 2009-11-12 US disclosed
WO-2009071668-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS BIOVITRUM AB (PUBL) (SE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281087-A1 Compounds II GPR119, FABP4, LIPC KDM1A 4310/4885CHRM4 1879/4885ADAM10 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.